Joshua van der Eerden

Mr. Joshua van der Eerden


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SBStacy Bedore
Stacy Bedore
JEJoshua van der Eerden
Joshua van der Eerden
FBFaizan Boghani
Faizan Boghani
SPSaloni Jayesh Patel
Saloni Jayesh Patel
SYSamer Yassin
Samer Yassin
VLVinata B Lokeshwar
Vinata B Lokeshwar
The clinical outcome of patients with muscle-invasive bladder cancer (MIBC) is poor despite the approval of neoadjuvant chemotherapy or immunotherapy to improve overall survival after cystectomy. MIBC subtypes, immune, transcriptome, metabolomic signatures, and mutation burden have the potential to predict treatment response but none have been incorporated into clinical practice, as tumor heterogeneity and lineage plasticity influence their efficacy. Using the PRISMA statement, we conducted a systematic review of the literature, involving 135 studies published within the last five years, to identify studies reporting on the prognostic value of protein-based biomarkers for response to neoadjuvant therapy in patients with MIBC. The studies were grouped based on biomarkers related to molecular subtypes, cancer stem cell, actin-cytoskeleton, epithelial–mesenchymal transition, apoptosis, and tumor-infiltrating immune cells. These studies show the potential of protein-based biomarkers, especially in the spatial context, to reduce the influence of tumor heterogeneity on a biomarker’s prognostic capability. Nevertheless, currently, there is little consensus on the methodology, reagents, and the scoring systems to allow reliable assessment of the biomarkers of interest. Furthermore, the small sample size of several studies necessitates the validation of potential prognostic biomarkers in larger multicenter cohorts before their use for individualizing neoadjuvant therapy regimens for patients with MIBC.

1 October 2025 in Urology Case Reports
Verified
Journal Article
Open access
SBStacy R. Bedore
Stacy R. Bedore
DSDanielle H. Shin
Danielle H. Shin
JEJoshua van der Eerden
Joshua van der Eerden
MTMorgan V. Town
Morgan V. Town
MTMartha K. Terris
Martha K. Terris
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1, such as pembrolizumab, are widely used for the treatment of various malignancies. These therapies, while typically less toxic than traditional chemotherapy, are associated with immune related adverse events which may affect the gastrointestinal tract, lungs, skin, liver, and less commonly the nervous system. Neurologic irAE are rare but carry high mortality rates. We present a case of seronegative myasthenia gravis in a patient treated with pembrolizumab for refractory bladder cancer. This case highlights the importance of early recognition of neurologic manifestations of irAE in patients receiving therapy with ICIs.

9 April 2025 in Urology Case Reports
Verified
Journal Article
Open access
SBStacy R. Bedore
Stacy R. Bedore
JEJoshua van der Eerden
Joshua van der Eerden
OSOm Vishwas Sakhalkar
Om Vishwas Sakhalkar
SASung Alexander
Sung Alexander
PSPablo J SantaMaria
Pablo J SantaMaria
BMBradley Morganstern
Bradley Morganstern
Rickets and other nutritional deficiencies have largely been eradicated in the industrialized world. However, strict adherence to modern diet trends such as veganism may leave individuals vulnerable to nutritional deficiencies if proper supplementation is not followed. The effects of such deficiencies due to diet trends, particularly in children, is not well documented as occurrences are rare. Here we present a case of a 3-year-old female fed a strict vegan diet which led to the development of nutritional calcipenic rickets, failure to thrive, and nephrolithiasis.